Cargando…
Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer
The purpose of our study was to determine the most accurate analytic method to define in vitro chemosensitivity, using clinical response as reference standard in prospective clinical trial, and to assess accuracy of adenosine triphosphate-based chemotherapy response assay (ATP-CRA). Forty-eight pati...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858825/ https://www.ncbi.nlm.nih.gov/pubmed/20436702 http://dx.doi.org/10.3346/jkms.2010.25.5.684 |
_version_ | 1782180455832879104 |
---|---|
author | Kim, Jee Hyun Lee, Keun-Wook Kim, Yeul Hong Lee, Kyung Hee Oh, Do Youn Kim, Joonhee Yang, Sung Hyun Im, Seock-Ah Choi, Sung Ho Bang, Yung-Jue |
author_facet | Kim, Jee Hyun Lee, Keun-Wook Kim, Yeul Hong Lee, Kyung Hee Oh, Do Youn Kim, Joonhee Yang, Sung Hyun Im, Seock-Ah Choi, Sung Ho Bang, Yung-Jue |
author_sort | Kim, Jee Hyun |
collection | PubMed |
description | The purpose of our study was to determine the most accurate analytic method to define in vitro chemosensitivity, using clinical response as reference standard in prospective clinical trial, and to assess accuracy of adenosine triphosphate-based chemotherapy response assay (ATP-CRA). Forty-eight patients with chemo-naïve, histologically confirmed, locally advanced or metastatic gastric cancer were enrolled for the study and were treated with combination chemotherapy of paclitaxel 175 mg/m(2) and cisplatin 75 mg/m(2) for maximum of six cycles after obtaining specimen for ATP-CRA. We performed the receiver operator characteristic curve analysis using patient responses by WHO criteria and ATP-CRA results to define the method with the highest accuracy. Median progression free survival was 4.2 months (95% confidence interval [CI]: 3.4-5.0) and median overall survival was 11.8 months (95% CI: 9.7-13.8) for all enrolled patients. Chemosensitivity index method yielded highest accuracy of 77.8% by ROC curve analysis, and the specificity, sensitivity, positive and negative predictive values were 95.7%, 46.2%, 85.7%, and 75.9%. In vitro chemosensitive group showed higher response rate (85.7% vs. 24.1%) (P=0.005) compared to chemoresistant group. ATP-CRA could predict clinical response to paclitaxel and cisplatin chemotherapy with high accuracy in advanced gastric cancer patients. Our study supports the use of ATP-CRA in further validation studies. |
format | Text |
id | pubmed-2858825 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | The Korean Academy of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-28588252010-05-01 Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer Kim, Jee Hyun Lee, Keun-Wook Kim, Yeul Hong Lee, Kyung Hee Oh, Do Youn Kim, Joonhee Yang, Sung Hyun Im, Seock-Ah Choi, Sung Ho Bang, Yung-Jue J Korean Med Sci Original Article The purpose of our study was to determine the most accurate analytic method to define in vitro chemosensitivity, using clinical response as reference standard in prospective clinical trial, and to assess accuracy of adenosine triphosphate-based chemotherapy response assay (ATP-CRA). Forty-eight patients with chemo-naïve, histologically confirmed, locally advanced or metastatic gastric cancer were enrolled for the study and were treated with combination chemotherapy of paclitaxel 175 mg/m(2) and cisplatin 75 mg/m(2) for maximum of six cycles after obtaining specimen for ATP-CRA. We performed the receiver operator characteristic curve analysis using patient responses by WHO criteria and ATP-CRA results to define the method with the highest accuracy. Median progression free survival was 4.2 months (95% confidence interval [CI]: 3.4-5.0) and median overall survival was 11.8 months (95% CI: 9.7-13.8) for all enrolled patients. Chemosensitivity index method yielded highest accuracy of 77.8% by ROC curve analysis, and the specificity, sensitivity, positive and negative predictive values were 95.7%, 46.2%, 85.7%, and 75.9%. In vitro chemosensitive group showed higher response rate (85.7% vs. 24.1%) (P=0.005) compared to chemoresistant group. ATP-CRA could predict clinical response to paclitaxel and cisplatin chemotherapy with high accuracy in advanced gastric cancer patients. Our study supports the use of ATP-CRA in further validation studies. The Korean Academy of Medical Sciences 2010-05 2010-04-21 /pmc/articles/PMC2858825/ /pubmed/20436702 http://dx.doi.org/10.3346/jkms.2010.25.5.684 Text en © 2010 The Korean Academy of Medical Sciences. http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Jee Hyun Lee, Keun-Wook Kim, Yeul Hong Lee, Kyung Hee Oh, Do Youn Kim, Joonhee Yang, Sung Hyun Im, Seock-Ah Choi, Sung Ho Bang, Yung-Jue Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer |
title | Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer |
title_full | Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer |
title_fullStr | Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer |
title_full_unstemmed | Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer |
title_short | Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer |
title_sort | individualized tumor response testing for prediction of response to paclitaxel and cisplatin chemotherapy in patients with advanced gastric cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858825/ https://www.ncbi.nlm.nih.gov/pubmed/20436702 http://dx.doi.org/10.3346/jkms.2010.25.5.684 |
work_keys_str_mv | AT kimjeehyun individualizedtumorresponsetestingforpredictionofresponsetopaclitaxelandcisplatinchemotherapyinpatientswithadvancedgastriccancer AT leekeunwook individualizedtumorresponsetestingforpredictionofresponsetopaclitaxelandcisplatinchemotherapyinpatientswithadvancedgastriccancer AT kimyeulhong individualizedtumorresponsetestingforpredictionofresponsetopaclitaxelandcisplatinchemotherapyinpatientswithadvancedgastriccancer AT leekyunghee individualizedtumorresponsetestingforpredictionofresponsetopaclitaxelandcisplatinchemotherapyinpatientswithadvancedgastriccancer AT ohdoyoun individualizedtumorresponsetestingforpredictionofresponsetopaclitaxelandcisplatinchemotherapyinpatientswithadvancedgastriccancer AT kimjoonhee individualizedtumorresponsetestingforpredictionofresponsetopaclitaxelandcisplatinchemotherapyinpatientswithadvancedgastriccancer AT yangsunghyun individualizedtumorresponsetestingforpredictionofresponsetopaclitaxelandcisplatinchemotherapyinpatientswithadvancedgastriccancer AT imseockah individualizedtumorresponsetestingforpredictionofresponsetopaclitaxelandcisplatinchemotherapyinpatientswithadvancedgastriccancer AT choisungho individualizedtumorresponsetestingforpredictionofresponsetopaclitaxelandcisplatinchemotherapyinpatientswithadvancedgastriccancer AT bangyungjue individualizedtumorresponsetestingforpredictionofresponsetopaclitaxelandcisplatinchemotherapyinpatientswithadvancedgastriccancer |